Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411562 | 1.00 | KEAP1 (0.63) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL5330046 | 0.84 | KDM4E (0.56) | KEAP1NFE2L2CYP2A6MAPTPKM | |
| SCHEMBL837538 | 0.84 | KEAP1 (0.54) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL14944882 | 0.80 | CYP2A6 (0.64) | KEAP1NFE2L2CYP2A6EPHX1CA2 | |
| SCHEMBL1421072 | 0.80 | CYP2A6 (0.54) | CYP2A6CA2MAPTSMN1; SMN2PKM | |
| SCHEMBL2466886 | 0.80 | CYP2A6 (0.54) | CYP2A6CA2MAPTSMN1; SMN2PKM | |
| SCHEMBL29373380 | 0.80 | CYP2A6 (0.54) | CYP2A6CA2MAPTSMN1; SMN2PKM | |
| SCHEMBL514509 | 0.80 | CYP2A6 (0.54) | CYP2A6CA2MAPTSMN1; SMN2PKM | |
| SCHEMBL514508 | 0.80 | CYP2A6 (0.54) | CYP2A6CA2MAPTSMN1; SMN2PKM | |
| SCHEMBL13995271 | 0.79 | KEAP1 (0.69) | KEAP1NFE2L2CYP2A6EPHX1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339193-B2 | CDP protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2022-05-24 | — | — | US | disclosed |
| CN-112513065-A | CDP protein secretion inhibitors | 科智生命科学公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3774850-A1 | CDP PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017233-A1 | CDP PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-01-21 | — | — | US | disclosed |
| WO-2019191527-A1 | CDP PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3081214-A2 | INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2384753-B1 | Hydantoin derivatives as inhibitors of cellular necrosis | BRIGHAM & WOMENS HOSPITAL (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8741942-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8143300-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2384753-A1 | Hydantoin derivatives as inhibitors of cellular necrosis | The Brigham and Women's Hospital, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110144169-A1 | Inhibitors of cellular necrosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1663184-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005077344-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF CELLULAR NECROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | KEAP1 1624/4885NFE2L2 4406/4885CYP2A6 2915/4885 |
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | KEAP1 1043/4885NFE2L2 874/4885CYP2A6 4707/4885 |
| US-11339193-B2 | CDP protein secretion inhibitors | SEC61G, SEC61A1, SEC61B | KEAP1 2010/4885NFE2L2 4136/4885CYP2A6 2909/4885 |
| US-20110144169-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | KEAP1 1043/4885NFE2L2 874/4885CYP2A6 4707/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | KEAP1 1821/4885NFE2L2 4524/4885CYP2A6 2934/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | KEAP1 1699/4885NFE2L2 4411/4885CYP2A6 2797/4885 |
| US-20210017233-A1 | CDP PROTEIN SECRETION INHIBITORS | SEC61G, SEC61A1, SEC61B | KEAP1 2010/4885NFE2L2 4136/4885CYP2A6 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.